Analysis
Coverage and analysis in analysis from the Peptidings newsroom.
Semaglutide Beat Tirzepatide on Heart Outcomes in 21,000-Patient Real-World Study
STEER linked semaglutide to 29% fewer major cardiac events than tirzepatide in patients with heart disease. Why outcomes, not weight loss, may decide.
UNSW and Queensland Researchers: Injectable Peptide Anti-Aging Trend Is Outrunning Its Evidence
Australian researchers from UNSW and UQ publish an evidence review on the injectable peptide anti-aging trend, finding the safety and efficacy data well behind the marketing.
The Three-Layered GLP-1 Access Crisis: Insurance Losses, a Medicare Delay, and a Pricing Experiment
24 million lost GLP-1 coverage, Medicare's BALANCE Model delayed, MFN pricing at $245/month. Three forces reshaping who can afford weight loss drugs.
GHK-Cu Is Now the Fastest-Growing Peptide in Consumer Search. The Evidence Hasn’t Caught Up.
GHK-Cu is now the fastest-growing peptide in consumer search—and the gap between interest and evidence has never been wider. Somewhere […]
A Patient Chose BPC-157 Over a Statin. A STAT News Physician Asks Why.
A physician writing in STAT News on April 3 described a patient who refuses to take a statin — a drug […]
MIT Technology Review: “Peptides Are Everywhere. Here’s What You Need to Know.”
MIT Technology Review published a feature on February 23 documenting what anyone in the peptide space already knew — and what […]